Literature DB >> 18074506

Appetite suppression and weight loss incidental to spinal cord stimulation for pain relief.

Eugene Pereira1, Allison Foster.   

Abstract

Spinal cord stimulation (SCS) uses electrical stimulation of the dorsal columns of the spinal cord to prevent the perception of intractable neuropathic pain signals, but its mechanisms and consequences of use are poorly understood. Two overweight female patients who were implanted with SCS systems (Precision; Advanced Bionics/Boston Scientific, Valencia, CA) reported better than 50% relief of their chronic back and leg pain. Unexpectedly, SCS stimulation was also associated with a tingling sensation in the viscera and a reduction in appetite. Both patients were thus able to reduce food intake at mealtimes and had lost about 9 kg in the first 4 months of SCS use, despite denying changes in exercise habits. The mechanism by which SCS can reduce the desire for food is unknown, but this and similar neuromodulation techniques may hold promise for weight loss in patients who fail other treatments or are not healthy enough for surgery.

Entities:  

Mesh:

Year:  2007        PMID: 18074506     DOI: 10.1007/s11695-007-9217-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  14 in total

Review 1.  The role of dorsal columns pathway in visceral pain.

Authors:  J Palecek
Journal:  Physiol Res       Date:  2004       Impact factor: 1.881

Review 2.  Applications of electrical pacing in the body.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2004-09       Impact factor: 4.129

Review 3.  Spinal cord stimulation for intractable pain: long-term follow-up.

Authors:  R B North
Journal:  J Spinal Disord       Date:  1990-12

4.  One-year experience with Tantalus: a new surgical approach to treat morbid obesity.

Authors:  Arthur Bohdjalian; Gerhard Prager; Ricardo Aviv; Shai Policker; Karin Schindler; Silke Kretschmer; Raphaela Riener; Johannes Zacherl; Bernhard Ludvik
Journal:  Obes Surg       Date:  2006-05       Impact factor: 4.129

Review 5.  A visceral pain pathway in the dorsal column of the spinal cord.

Authors:  W D Willis; E D Al-Chaer; M J Quast; K N Westlund
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

6.  Microchip vagal pacing reduces food intake and body mass.

Authors:  J Sobocki; P J Thor; J Uson; I Diaz-Guemes; M Lipinski; C Calles; S Pascual
Journal:  Hepatogastroenterology       Date:  2001 Nov-Dec

Review 7.  Neural-immune gut-brain communication in the anorexia of disease.

Authors:  Gary J Schwartz
Journal:  Nutrition       Date:  2002-06       Impact factor: 4.008

Review 8.  Spinal cord stimulation in chronic pain: a review of the evidence.

Authors:  M L Carter
Journal:  Anaesth Intensive Care       Date:  2004-02       Impact factor: 1.669

9.  Spinal cord stimulation in treatment of chronic benign pain: challenges in treatment planning and present status, a 22-year experience.

Authors:  Krishna Kumar; Gary Hunter; Denny Demeria
Journal:  Neurosurgery       Date:  2006-03       Impact factor: 4.654

Review 10.  Disuse and deconditioning in chronic low back pain: concepts and hypotheses on contributing mechanisms.

Authors:  Jeanine A Verbunt; Henk A Seelen; Johan W Vlaeyen; Geert J van de Heijden; Peter H Heuts; Kees Pons; J Andre Knottnerus
Journal:  Eur J Pain       Date:  2003       Impact factor: 3.931

View more
  2 in total

1.  Percutaneous electrical neurostimulation of dermatome T6 for appetite reduction and weight loss in morbidly obese patients.

Authors:  Jaime Ruiz-Tovar; Inmaculada Oller; María Diez; Lorea Zubiaga; Antonio Arroyo; Rafael Calpena
Journal:  Obes Surg       Date:  2014-02       Impact factor: 4.129

2.  Percutaneous Electrical Neurostimulation (PENS) of Dermatome T6 with an Ambulatory Self-applied Patch vs PENS of Dermatome T6 with Conventional Procedure: Effect on Appetite and Weight Loss in Moderately Obese Patients.

Authors:  Mohammed Abdel-Kadar
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.